
Aera Therapeutics: A biotech firm enhancing genetic medicines' potential with proprietary protein nanoparticle delivery tech.
Aera Therapeutics, founded with a mission to unlock the full potential of genetic medicines, leverages its proprietary protein nanoparticle (PNP) delivery platform to overcome the limitations of current delivery technologies. The company's innovative platform, based on endogenous human proteins, aims to extend the reach of genetic medicines to various tissues and applications, thereby benefiting a broader range of patients across multiple disease areas.
Notable affiliated individuals and investors include leading figures in biotechnology and venture capital. Aera Therapeutics has achieved significant milestones in advancing its PNP delivery technology, positioning itself as a key player in the genetic medicine landscape. The company's impact is marked by its potential to transform therapeutic approaches and improve patient outcomes in diverse medical fields.

Aro Biotherapeutics
arobiotx.com

Affinia Therapeutics
affiniatx.com

Alaya.bio
alaya.bio

ReviR Therapeutics
revirtx.com

Kelonia Therapeutics
keloniatx.com

Apertura Gene Therapy
aperturagtx.com

Aureka Biotechnologies
aurekabio.com

Lattice Therapeutics

Alltrna
alltrna.com

ProFound Therapeutics
profoundtx.com

Frontera Therapeutics

Orna Therapeutics

Aer Therapeutics

Phoreus Biotechnology
phoreusbiotech.com

Faze Medicines
fazemed.com
Companies similar to Aera Therapeutics include Aro Biotherapeutics, Affinia Therapeutics, Alaya.bio and ReviR Therapeutics.
Aera Therapeutics was founded in 2021.
Aera Therapeutics' headquarters is located in Boston, MA, US.
Aera Therapeutics' most recent funding round was for $193M (USD) in February 2023.
As of Feb 16, 2023, Aera Therapeutics has raised a total of $193M (USD).
Aera Therapeutics has 175 employees as of Feb 4, 2024.